Business Context and Reporting Period
This Form 8-K, filed on August 29, 2023, reports events occurring on August 28, 2023, for E.L.F. Beauty, Inc. (the "Company"). The filing details the entry into a definitive agreement to acquire Naturium LLC and related entities, alongside an amendment to the Company's existing credit facility to facilitate the transaction.
Key Financial Metrics and Transaction Terms
- Total Consideration: $355.0 million.
- Payment Structure:
- Stock Consideration: $72.02 million in Company common stock (valued at $124.6760 per share).
- Cash Consideration: The remainder funded by an Incremental Term Loan, borrowings on the revolving credit facility, and existing cash on hand.
- Debt Financing: The Company amended its Credit Agreement to allow for an Incremental Term Loan of up to $115.0 million.
- Loan Terms:
- Interest Rate: SOFR + 1.50% to 2.375% (or Alternate Base Rate + 0.50% to 1.375%), based on leverage ratios.
- Amortization: 5.00% per annum, payable in quarterly installments starting December 31, 2023.
- Insurance: A representations and warranties insurance policy with a coverage limit of $35 million.
Material Changes and Transaction Conditions
The filing represents a material change in the Company's capital structure and business scope through the proposed acquisition. Key conditions to closing include:
- Expiration of the Hart-Scott Rodino Antitrust waiting period.
- Approval for listing the issued shares on the New York Stock Exchange.
- Absence of legal impediments or material adverse effects regarding Naturium.
- Expected Closing Date: Around September 30, 2023.
- Lock-Up Restrictions: Recipients of stock consideration are subject to lock-up periods of one year, with 50% of the locked stock releasing after six months.
Outlook, Risks, and Management Commentary
Management intends to use the Incremental Term Loan, revolving credit facility, and cash on hand to consummate the acquisition. The transaction is not subject to a financing condition. The filing includes standard forward-looking statements regarding the timeline and integration of the acquired business.
Identified Risks:
- Failure to obtain required regulatory approvals in a timely manner.
- Inability to successfully integrate Naturium or realize anticipated benefits.
- Unanticipated costs associated with the acquisition or integration.
- Changes in tax laws or pre-acquisition non-compliance by Naturium.
- Termination of the agreement if closing does not occur by December 28, 2023, or if material breaches occur.
Investor Verification Checklist
- Verify the final closing date and whether the September 30, 2023 target is met.
- Confirm the exact amount of the Incremental Term Loan drawn and the final interest rate margin applied.
- Monitor regulatory approval status, specifically the Hart-Scott Rodino waiting period expiration.
- Review the upcoming Form 10-Q for the full text of the Purchase Agreement and Credit Amendment.
- Assess the impact of the $355 million outflow and new debt on the Company's liquidity and leverage ratios post-closing.